OBJECT: Patients with aneurysmal subarachnoid hemorrhage (SAH) are at high risk for delayed cerebral ischemia (DCI) and stroke. Epoxyeicosatrienoic acids (EETs) play an important role in cerebral blood flow regulation and neuroprotection after brain injury. Polymorphisms in the gene for the enzyme soluble epoxide hydrolase (sEH), which inactivates EETs, are associated with ischemic stroke risk and neuronal survival after ischemia. This prospective observational study of patients with SAH compares vital and neurologic outcomes based on functional polymorphisms of sEH. METHODS: Allelic discrimination based on quantitative real-time polymerase chain reaction was used to differentiate wild-type sEH from K55R heterozygotes (predictive of increased sEH activity and reduced EETs) and R287Q heterozygotes (predictive of decreased sEH activity and increased EETs). The primary outcome was new stroke after SAH. Secondary outcomes were death, Glasgow Outcome Scale score, and neurological deterioration attributable to DCI. RESULTS: Multivariable logistic regression models adjusted for age at admission and Glasgow Coma Scale scores revealed an increase in the odds of new stroke (OR 5.48 [95% CI 1.51-19.91]) and death (OR 7.52 [95% CI 1.27-44.46]) in the K55R group, but no change in the odds of new stroke (OR 0.56 [95% CI 0.16-1.96]) or death (OR 3.09 [95% CI 0.51-18.52]) in patients with R287Q genotype, compared with wild-type sEH. The R287Q genotype was associated with reduced odds of having a Glasgow Outcome Scale score of ≤ 3 (OR 0.23 [95% CI 0.06-0.82]). There were no significant differences in the odds of neurological deterioration due to DCI. CONCLUSIONS: Genetic polymorphisms of sEH are associated with neurological and vital outcomes after aneurysmal SAH.
OBJECT: Patients with aneurysmal subarachnoid hemorrhage (SAH) are at high risk for delayed cerebral ischemia (DCI) and stroke. Epoxyeicosatrienoic acids (EETs) play an important role in cerebral blood flow regulation and neuroprotection after brain injury. Polymorphisms in the gene for the enzyme soluble epoxide hydrolase (sEH), which inactivates EETs, are associated with ischemic stroke risk and neuronal survival after ischemia. This prospective observational study of patients with SAH compares vital and neurologic outcomes based on functional polymorphisms of sEH. METHODS: Allelic discrimination based on quantitative real-time polymerase chain reaction was used to differentiate wild-type sEH from K55R heterozygotes (predictive of increased sEH activity and reduced EETs) and R287Q heterozygotes (predictive of decreased sEH activity and increased EETs). The primary outcome was new stroke after SAH. Secondary outcomes were death, Glasgow Outcome Scale score, and neurological deterioration attributable to DCI. RESULTS: Multivariable logistic regression models adjusted for age at admission and Glasgow Coma Scale scores revealed an increase in the odds of new stroke (OR 5.48 [95% CI 1.51-19.91]) and death (OR 7.52 [95% CI 1.27-44.46]) in the K55R group, but no change in the odds of new stroke (OR 0.56 [95% CI 0.16-1.96]) or death (OR 3.09 [95% CI 0.51-18.52]) in patients with R287Q genotype, compared with wild-type sEH. The R287Q genotype was associated with reduced odds of having a Glasgow Outcome Scale score of ≤ 3 (OR 0.23 [95% CI 0.06-0.82]). There were no significant differences in the odds of neurological deterioration due to DCI. CONCLUSIONS: Genetic polymorphisms of sEH are associated with neurological and vital outcomes after aneurysmal SAH.
Authors: Myriam Fornage; Craig R Lee; Peter A Doris; Molly S Bray; Gerardo Heiss; Darryl C Zeldin; Eric Boerwinkle Journal: Hum Mol Genet Date: 2005-08-22 Impact factor: 6.150
Authors: Michael N Diringer; Thomas P Bleck; J Claude Hemphill; David Menon; Lori Shutter; Paul Vespa; Nicolas Bruder; E Sander Connolly; Giuseppe Citerio; Daryl Gress; Daniel Hänggi; Brian L Hoh; Giuseppe Lanzino; Peter Le Roux; Alejandro Rabinstein; Erich Schmutzhard; Nino Stocchetti; Jose I Suarez; Miriam Treggiari; Ming-Yuan Tseng; Mervyn D I Vergouwen; Stefan Wolf; Gregory Zipfel Journal: Neurocrit Care Date: 2011-09 Impact factor: 3.210
Authors: Ines P Koerner; Rachel Jacks; Andrea E DeBarber; Dennis Koop; Peizhong Mao; David F Grant; Nabil J Alkayed Journal: J Neurosci Date: 2007-04-25 Impact factor: 6.167
Authors: DeWitte T Cross; David L Tirschwell; Mary Ann Clark; Dan Tuden; Colin P Derdeyn; Christopher J Moran; Ralph G Dacey Journal: J Neurosurg Date: 2003-11 Impact factor: 5.115
Authors: Alejandro A Rabinstein; Jonathan A Friedman; Stephen D Weigand; Robyn L McClelland; Jimmy R Fulgham; Edward M Manno; John L D Atkinson; Eelco F M Wijdicks Journal: Stroke Date: 2004-06-24 Impact factor: 7.914
Authors: Dominic A Siler; Yosef A Berlow; Ayaka Kukino; Catherine M Davis; Jonathan W Nelson; Marjorie R Grafe; Hirohisa Ono; Justin S Cetas; Martin Pike; Nabil J Alkayed Journal: Stroke Date: 2015-05-19 Impact factor: 7.914
Authors: Babak Behnam Azad; Daniel P Holt; Hayden T Ravert; Andrew G Horti; Robert F Dannals Journal: J Labelled Comp Radiopharm Date: 2018-05-07 Impact factor: 1.921
Authors: Dominic A Siler; Ross P Martini; Jonathan P Ward; Jonathan W Nelson; Rohan N Borkar; Kristen L Zuloaga; Jesse J Liu; Stacy L Fairbanks; Jeffrey S Raskin; Valerie C Anderson; Aclan Dogan; Ruikang K Wang; Nabil J Alkayed; Justin S Cetas Journal: Neurocrit Care Date: 2015-04 Impact factor: 3.210
Authors: Hesham T Ghonim; Sumedh S Shah; John W Thompson; Sudheer Ambekar; Eric C Peterson; Mohamed Samy Elhammady Journal: J Vasc Interv Neurol Date: 2016-01
Authors: Akinyemi Oni-Orisan; Sharon Cresci; Philip G Jones; Katherine N Theken; John A Spertus; Craig R Lee Journal: Prostaglandins Other Lipid Mediat Date: 2018-08-07 Impact factor: 3.072
Authors: Andrew G Horti; Yuchuan Wang; Il Minn; Xi Lan; Jian Wang; Raymond C Koehler; Nabil J Alkayed; Robert F Dannals; Martin G Pomper Journal: J Nucl Med Date: 2016-07-14 Impact factor: 10.057